Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

702 results about "Diagnostic marker" patented technology

Diagnostic marker of acute myelogenous leukemia prognosis model as well as application and prediction method thereof

The invention discloses a diagnostic marker of an acute myelogenous leukemia prognosis model as well as application and a prediction method of the diagnostic marker, and relates to the field of acute myelogenous leukemia prognosis research. The prognosis model is a prognosis model of acute myelogenous leukemia based on eight clinical characteristics, namely the disease age, the LDH level during disease, the RUNX1 gene, the KMT2A gene, the TP53 gene, the DMNT3A gene, the CBFB:: MYH11 gene and whether the first course of treatment is relieved or not; the construction method comprises the following steps of: sequentially carrying out univariate Cox regression analysis, Kaplan-Meier survival analysis and multivariate Cox regression analysis on clinical data of a patient from a data set and RNA sequencing data of peripheral blood and bone marrow samples in combination with survival information, further weighting an expression level according to an obtained regression coefficient, and carrying out quantitative analysis on the expression level. And establishing a prognosis model of acute myelogenous leukemia based on eight clinical characteristics. The acute myelogenous leukemia prognosis model disclosed by the invention has a relatively good evaluation effect.
Owner:ZHEJIANG UNIV

Application of secretory LCTL in preparation of biomarker for chronic kidney disease diagnosis

The invention belongs to the technical field of biological medicines, and particularly relates to application of secretory lactase-like protein (LCTL) as a diagnostic marker in preparation of a diagnostic kit for chronic kidney diseases. According to the present invention, the secretory form of the LCTL is found for the first time, the secretory LCTL content in the human serum is detected by using the existing commercial ELISA kit for the first time, and the further research finds that the secretory LCTL content in the serum of the chronic kidney disease patient is significantly reduced compared with the normal person; and the content of the LCTL in the serum is obviously related to the renal function impairment degree and proteinuria degree of the patient, so that the application of the secretory LCTL in preparing the biomarker for diagnosing the chronic kidney disease is provided for the first time. The invention provides a new method for chronic kidney disease diagnosis, and has important clinical significance and commercial value.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Novel tsRNA high-sensitivity detection kit based on CRISPR / Cas13a-Cas14a

The invention discloses a novel tsRNA high-sensitivity detection kit based on CRISPR (clustered regularly interspaced short palindromic repeats) / Cas13a-Cas14a, and belongs to the field of tumor marker detection. The tsRNA (tRNA-derived small RNA) is a diagnostic marker which is found recently and has great potential. In order to realize the clinical transformation of tsRNA as soon as possible, the tsRNA detection kit is developed on the basis of nuclease P1 combined with CRISPR / Cas13a-Cas14a linkage dual systems, and comprehensive, ultra-sensitive, high-specificity, low-cost and rapid tsRNA detection is realized through multiple signal amplification. Compared with the traditional technology, the sensitivity of the method is improved by 105-107 times, 1% of tsRNA in the mixture can be detected, and the method has more advantages in clinical application. Therefore, a new scheme is provided for application of the tsRNA in clinical diagnosis of diseases, and meanwhile, a reliable technology is provided for mechanism research of the tsRNA in occurrence and development of the diseases.
Owner:THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV

Pulmonary arterial hypertension related PLEKHH2 gene mutation and application thereof

The invention discloses PLEKHH2 gene mutation related to pulmonary arterial hypertension and application of the PLEKHH2 gene mutation. According to the invention, a mutant PLEKHH2 protein (p.I1245T, p.S658F, p.P542S, p.A609T, p.Y735C, p.R797X and p.T1240S) and / or a mutant PLEKHH2 gene (c.3734Tgt; c, c, 1973Cgt, c, 1973Cgt T, c.1624Cgt, c. 1624Cgt; t, c.1825 Ggt; a, c, 2204Agt; g, c, 2389Cgt; t, c, 3718Agt; t) can be used as a diagnostic marker of pulmonary arterial hypertension, lays a foundation for early screening, diagnosis, auxiliary diagnosis, risk prediction and pre-pregnancy early warning of pulmonary arterial hypertension, and has important scientific research and clinical application values.
Owner:FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

Application of macrophage Angulin-1 in preparation of drugs and diagnostic products for preventing and / or treating atherosclerosis and related diseases

The invention belongs to the technical field of biological medicines, and particularly relates to application of a macrophage Angulin-1 gene and / or an Angulin-1 protein in preparation of medicines and diagnostic products for preventing and / or treating atherosclerosis and related diseases. Research finds that plaque and necrotic core areas of an atherosclerosis animal model are remarkably increased due to macrophage Angulin-1 gene knockout, and disease development is promoted; and the recovery of the expression level of Angulin-1 significantly inhibits the development of lesion. Cell experiments show that Angulin-1 reduces intake of oxidized low-density lipoprotein by down-regulating expression of macrophage LOX-1, so that formation of foam cells is inhibited. Therefore, the macrophage Angulin-1 can be used as an atherosclerosis drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.
Owner:BINZHOU MEDICAL COLLEGE

Application of protein in small extracellular vesicles as prostate cancer diagnostic marker

ActiveCN119125561AHigh AUC valueHigh specificity and sensitivityMaterial analysisAntigenPsa antigen
The invention discloses application of small extracellular endovesicular protein as a prostatic cancer diagnostic marker, and is characterized in that the small extracellular endovesicular protein is plasma sample sEV protein LAMB1 and / or urine sample sEV protein Histone H4, and the plasma sample sEV protein LAMB1 is applied as a metastatic prostatic cancer diagnostic marker. The sEV protein LAMB1 of the plasma sample is combined with a prostate specific antigen to serve as metastatic prostate cancer; the application of the sEV protein Histone H4 in the urine sample as a prostate cancer grading diagnosis marker, the application of the sEV protein Histone H4 in the urine sample as a high-risk prostate cancer diagnosis marker and the application of the combination of the sEV protein Histone H4 in the urine sample and a prostate specific antigen as the high-risk prostate cancer diagnosis marker have the advantages of high sensitivity and strong specificity.
Owner:NINGBO FIRST HOSPITAL

Rheumatoid arthritis diagnosis product and system and application thereof

The invention discloses a rheumatoid arthritis diagnosis product and system and application thereof, and relates to the technical field of rheumatoid arthritis. The diagnostic marker comprises calcium, a ratio of arginine to ornithine, a ratio of phenylalanine to tyrosine, an anti-cyclic citrullinated peptide antibody and lysine. The invention provides a biomarker capable of accurately diagnosing rheumatoid arthritis RA, which comprises five indexes, namely calcium, the proportion of arginine to ornithine, the proportion of phenylalanine to tyrosine, an anti-cyclic citrullinated peptide antibody (anti-CCP) and lysine. The five indexes have the technical advantages of few indexes and excellent diagnosis performance. A diagnosis model constructed based on the five indexes has good sensitivity, specificity and accuracy. The kit can be used for diagnosis of rheumatoid arthritis.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Diagnostic marker for systemic lupus erythematosus and application thereof

The invention provides a diagnostic marker for systemic lupus erythematosus and application of the diagnostic marker, and belongs to the technical field of biological medicine. The diagnostic marker is at least one protein of PDGFA (Platelet Derivative Growth Factor Amplification), APOD (Adenosine Polymerase Chain Reaction), CFHR5, AMDHD1 and SCGB3A1; the amino acid sequence of the PDGFA is as shown in SED ID NO. 1; the amino acid sequence of the APOD is as shown in SED ID NO. 2; the amino acid sequence of the CFHR5 is as shown in SED ID NO.3; the amino acid sequence of AMDHD1 is as shown in SED ID NO. 4; and the amino acid sequence of the SCGB3A1 is as shown in SED ID (Sequence of Identification) NO.5. According to the present invention, the five proteins are adopted as the SLE disease diagnosis biomarker independently or in the combination manner, such that advantages of high accuracy, high sensitivity and high specificity are provided, and the new target spot is provided for the diagnosis, the intervention improvement and the like of the SLE patient.
Owner:JIANGXI HERBFINE HI TECH +1

Molecular model established by detecting serum specimen based on proteomics and used for assisting in evaluating renal injury progress of diabetic nephropathy as well as construction method and application of molecular model

The invention relates to a molecular model established based on proteomics detection serum specimens and used for assisting in evaluating the renal injury progress of diabetic nephropathy as well as a construction method and application of the molecular model, new disease diagnosis markers can be found, and an existing disease diagnosis system can be optimized; according to the technical scheme, a proteomics technology is combined with various medical diagnosis technologies such as experiments and images through research thinking logic of evidence-based medicine and clinical epidemiology so as to diagnose whether a patient suffers from diseases or not and identify different diseases, and the molecular model is formed by combining proteins P23396 + P0CG47 + Q9NYQ8 + P63241, according to the present invention, the protein composition in the sample is detected by using the high-throughput mass spectrometry means, the difference of the diabetic nephropathy disease group and the non-disease group on the proteomics level is compared, the biomarker for the disease progress auxiliary evaluation model construction is screened, and the new scheme is provided for the disease progress auxiliary evaluation of the diabetic nephropathy.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Use of GPR1 as target in preparing endometriosis-related diagnostic and / or therapeutic formulation

PCT designated stage expiredWO2025076775A1Microbiological testing/measurementDeep infiltrating endometriosisOvarian Endometriosis
A use of a GPR1 as a target in preparing an endometriosis-related diagnostic and / or therapeutic formulation, relating to the technical field of biomedicine. The present invention provides a use of a GPR1 target as a diagnostic marker in preparing a reagent or kit for diagnosing endometriosis. The endometriosis is selected from one of uterosacral ligament endometriosis, peritoneal endometriosis, rectovaginal endometriosis, deep infiltrating endometriosis, and ovarian endometriosis. The present invention discovers that the expression of the GPR1 is significantly increased in endometriosis tissues and cells, indicating that the GPR1 can be used as a diagnostic marker for endometriosis. It has been discovered in in-vitro and in-vivo models that GPR1 knockout significantly inhibits the abilities of hEM15A cells to proliferate, migrate, and invade and the growth of ectopic foci in animals, indicating that the GPR1 can be used as a new intervention target for clinically treating endometriosis.
Owner:SHENZHEN INST OF ADVANCED TECH

Plasma metabolism diagnosis marker and diagnosis system for depression of children and adolescents

The invention relates to the technical field of diagnosis markers and diagnosis methods for mental diseases of children and adolescents, in particular to a plasma metabolism diagnosis marker and diagnosis system for depression of children and adolescents. The plasma metabolism diagnosis marker comprises at least one of cyclic adenosine monophosphate, methylpyridine, unsaturated undecylenyl carnitine, histidine, prolyl hydroxyproline, tryptophan and glucuronic acid. According to the scheme, non-target metabonomics data is analyzed, and seven candidate diagnostic markers for depression of children and adolescents are screened and determined from common differential metabolites. Then, through targeted metabonomics research, diagnostic markers and combinations thereof with ideal diagnostic effects are determined, and then a diagnostic model is constructed. And a sex factor is also incorporated into the diagnosis model, so that the diagnosis effect is further improved. According to the technical scheme, the technical problem that in the prior art, reliability and popularization potential of depression plasma metabolism biomarkers of children and adolescents are not ideal can be solved, and the depression plasma metabolism biomarkers have ideal popularization and application prospects.
Owner:THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY +1

Biomarker combination for assessing risk of adenoma and colorectal cancer, and use thereof

Disclosed are a biomarker combination for assessing the risk of adenoma and colorectal cancer, and the use thereof, in particular a metabolic marker for assessing the risk of adenoma and colorectal cancer of a subject, and the use thereof in the preparation of a diagnostic product for evaluating the risk of adenoma and colorectal cancer. The diagnostic marker has the characteristics of high sensitivity and specificity, has higher sensitivity and specificity for early colorectal cancer diagnosis, and can be used for the early discovery of colorectal cancer, so as to buy time for patients, allow treatment to be started as soon as possible, and improve the clinical treatment effect.
Owner:HUMAN METABOLOMICS INST INC

Idiopathic pulmonary fibrosis biomarkers and methods of production and use thereof

Methods of determining the presence, severity, and / or susceptibility of idiopathic pulmonary fibrosis (IPF) in an individual are disclosed. The method utilizes at least one diagnostic marker of the dynamic process of extracellular matrix synthesis and / or extracellular matrix degradation from the sample. The at least one diagnostic marker may be selected from the group consisting of tissue metalloproteinase inhibitor 1 (TIMP1), hyaluronic acid (HA), and / or type III procollagen N-terminal propeptide (PIIINP).
Owner:SIEMENS HEALTHCARE DIAGNOSTICS INC

Metabolic biomarker for predicting cardiovascular disease risk of senile subclinical hypothyroidism patient and application of metabolic biomarker

The invention relates to a metabolic biomarker for predicting the cardiovascular disease risk of a patient with senile subclinical hypothyroidism and application of the metabolic biomarker. The marker comprises inosine, arachidonic acid, arginine, phenylalanine and glycocholic acid. According to the method, metabolite information of each plasma sample in a research queue is obtained by establishing an elderly SCH and concurrent CVD crowd queue and detecting by adopting a high performance liquid chromatography-mass spectrometry technology, and a targeted metabolic content map is established. According to the matrix expression of the metabolic marker, in combination with clinical follow-up visit data, a model is constructed by using machine learning Lasso-cox, and a clinical prediction model of the CVD risk of the elderly SCH patient is constructed to guide precise diagnosis and treatment of the elderly SCH. The invention further provides a kit containing the diagnostic marker suitable for predicting the CVD risk of the elderly SCH, and the kit can be used for predicting the CVD risk of the elderly SCH.
Owner:NANJING GULOU HOSPITAL GRP SUQIAN HOSPITAL CO LTD

Application of GPR161 as diagnosis marker and treatment target of acute distress syndrome

The invention belongs to the technical field of biomedicine, and particularly relates to application of GPR161 as an acute distress syndrome diagnostic marker and a therapeutic target. Experiments prove that the expression level of GPR161 in peripheral blood mononuclear cells of a patient with the acute respiratory distress syndrome is remarkably increased, and the expression quantity of the GPR161 is positively correlated with the severity of the disease, so that the GPR161 gene or GPR161 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the acute respiratory distress syndrome; a reagent for inhibiting GPR161 gene expression or protein activity can be used for preparing a medicine for treating the acute respiratory distress syndrome. The invention provides a new strategy for diagnosis, monitoring and targeted drug development of ARDS, and has important clinical application value.
Owner:ANHUI MEDICAL UNIV

B-cell lymphoma early diagnosis marker, cross-species screening method based on lamprey and application

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.
Owner:LIAONING NORMAL UNIVERSITY

Electroencephalogram data transmission method combining lossless and lossy compression

The invention provides an electroencephalogram data transmission method combining lossless and lossy compression, belongs to the field of electroencephalogram data transmission and compression processing, and is used for solving the problems of low transmission efficiency of pure lossless compression and easy loss of key diagnosis information of pure lossy compression in related technologies. According to the method, multi-dimensional features of electroencephalogram data are extracted, a key area and a non-key area are divided, lossless compression and lossy compression processing are adopted respectively, the area division proportion is dynamically adjusted in combination with transmission bandwidth, signal features and application scenes, and corresponding data are transmitted through dual protocols. The transmission efficiency can be improved while the clinical diagnosis marker and the core characteristics are reserved, and the scene adaptability and the transmission reliability are achieved at the same time.
Owner:CLP CLOUD BRAIN (TIANJIN) TECH CO LTD

Active tuberculosis diagnostic marker, kit and application thereof

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.
Owner:SHANGHAI PULMONARY HOSPITAL (SHANGHAI OCCUPATIONAL DISEASE PREVENTION & CONTROL INSTITUTE)

Application of GPR1 as target spot in preparation of endometriosis related diagnosis and / or treatment preparation

PendingCN119824080AMicrobiological testing/measurementBiological testingDeep infiltrating endometriosisOvarian Endometriosis
The invention discloses application of GPR1 as a target spot in preparation of endometriosis related diagnosis and / or treatment preparations, and belongs to the technical field of biological medicines. The invention provides application of a GPR1 target spot serving as a diagnostic marker in preparation of a reagent or a kit for diagnosing endometriosis. The endometriosis is selected from one of a uterus-sacral ligament type endometriosis, a peritoneal type endometriosis, a rectum-vagina type endometriosis, a deep infiltration type endometriosis and an ovarian type endometriosis. The invention discovers that the expression of GPR1 in endometriosis tissues and cells is obviously increased, which prompts that GPR1 can be used as a diagnostic marker of endometriosis. In-vitro and in-vivo models find that the knockout of GPR1 significantly inhibits the proliferation, migration and invasion ability of hEM15A cells and the growth of ectopic lesions in animals, indicating that GPR1 can be used as a new intervention target for clinical treatment of endometriosis.
Owner:SHENZHEN INST OF ADVANCED TECH

Application of circular RNA Circ3426 as colorectal cancer diagnostic marker and therapeutic target

The invention discloses application of annular RNACirc3426 as a diagnostic marker and a therapeutic target of colorectal cancer. Experiments show that the Circ3426 is highly expressed in colorectal cancer cells and patient serum, and prove that the Circ3426 has good stability, and an ROC curve shows that the Circ3426 has good capacity of diagnosing colorectal cancer. Meanwhile, it is found that the molecule can promote migration and invasion ability of colorectal cancer cells, nude mouse subcutaneous tumor formation experiments prove that knock-down Circ3426 inhibits growth of tumors, and it is indicated that the molecule can serve as a treatment target of colorectal cancer. The invention provides a new diagnostic marker and a treatment target for colorectal cancer, and provides a new thought and direction for CRC diagnosis and treatment.
Owner:重庆医科大学国际体外诊断研究院

Application of index for representing intestinal flora metabolism homeostasis in autism early diagnosis kit

The invention relates to the technical field of biochemical diagnosis. The invention provides application of an index for representing intestinal flora metabolism homeostasis in an infantile autism early diagnosis kit. The index is an index for metabolic balance of gamma-aminobutyric acid and glutamic acid. Metabolic destabilization between gamma-aminobutyric acid (GABA) and glutamic acid (Glu) in intestinal flora is an important feature of children with light autism at the age of 3-6. According to the invention, an index for representing metabolic balance of GABA and Glu, namely a GABA / Glu ratio, is taken as a diagnostic marker for early screening of autism. The diagnostic marker not only has important application in clinical diagnosis, but also provides a new view angle and tool for scientific research, and is used for exploring and understanding a biological basis of autism. Detection of GABA and Glu can be rapidly carried out in a laboratory, subjectivity of clinical workers can be effectively avoided through obtained results, and mild ASD children can be effectively and objectively screened.
Owner:THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN

CircRNA (Ribonucleic Acid) as cell senescence marker and regulation and control target and application of circRNA

The invention discloses an application of a circRNA molecule as a diagnostic marker in a cell senescence diagnostic kit and an application of the circRNA molecule as a cell senescence treatment target. According to the application disclosed by the invention, the circHERC1 is found to be low in expression in natural aging and aging-inducing cell models, and the circHERC1 is over-expressed in endothelial cells, so that the multiplication capacity of the endothelial cells can be improved, the telomere length of the cells can be effectively prolonged, telomerase can be activated, the positive rate of beta-galactosidase of the cells can be reduced, and the expression quantity of aging-related proteins can be reduced.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Novel method for identifying diagnostic marker peak of protein citrullination through mass spectrum

The invention relates to a novel method for identifying a diagnostic marker peak of protein citrullination by mass spectrometry. A gas phase fragmentation pathway of citrullinated peptide is explored, a characteristic neutral loss is found, namely, the neutral loss of 43.0058 Da is matched with release of an isocyanate group of citrullinated ureido, the two modifications can be distinguished when the corresponding neutral loss is detected, and citrullinated modification can be accurately and quickly confirmed. When secondary mass spectrum data are retrieved, an anti-library is additionally added to calculate the false positive rate caused by random matching, and a common pollution library is added into a database to eliminate the influence of pollution protein in an identification result; the mass error tolerance is set in a targeted manner, and the accuracy of mass spectrum data retrieval and the diagnosis accuracy of protein citrullination are improved. The process of converting arginine into citrulline can be diagnosed with high specificity, the technology is a key technology for realizing polypeptide sequencing and post-translational modification analysis, and the specific citrulline part in the protein can be determined.
Owner:JINGJIE PTM BIOLAB HANGZHOU CO LTD

Multi-element machine learning model-based cross-species lung disease feature gene screening method and system, electronic system and storage device

The invention provides a multi-element machine learning model-based cross-species lung disease characteristic gene screening method and system, an electronic system and a storage device. The method comprises the following steps of: acquiring single cell / transcriptome data related to mouse lung diseases from a public database and preprocessing the single cell / transcriptome data; training the model by adopting six machine learning algorithms and outputting a gene importance score; calculating the weight according to the model performance and normalizing the score; and integrating the cross-species scores through a weighted fusion formula, and outputting a feature gene list and a visual report. The system comprises a data acquisition and preprocessing module, a multi-element machine learning model training module, a weight calculation and normalization module, a cross-species comprehensive scoring module and a result output module. The screening accuracy, stability and generalization ability are improved through multi-algorithm integration and cross-species fusion, and the method can be widely applied to the fields of mechanism research of lung diseases, diagnosis marker development and drug target verification.
Owner:RES CENT FOR ECO ENVIRONMENTAL SCI THE CHINESE ACAD OF SCI

Application of DHX58 as diagnostic marker and therapeutic target of rheumatoid arthritis

The invention belongs to the technical field of biomedicine, and particularly relates to application of DHX58 as a diagnostic marker and a therapeutic target of rheumatoid arthritis. Experiments prove that the DXH58 level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably increased, DHX58 and rheumatoid arthritis are positively correlated, and the DHX58 gene or DHX58 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of rheumatoid arthritis. Experiments prove that the targeted DHX58 can be used as an effective way for treating rheumatoid arthritis. The application has important meanings for researching the effect of DHX58 in rheumatoid arthritis, understanding the mechanism of RA disease and developing a new treatment strategy.
Owner:ANHUI MEDICAL UNIV

Improved polynucleotide sequence detection method

Disclosed is an improved polynucleotide sequence detection method suitable for testing for the presence of a large number of diagnostic markers, including those used in the identification of cancer, infectious disease and transplant organ rejection.
Owner:BIOFIDELITY LTD

METHOD FOR PREDICTION OF FUTURE CARDIOVASCULAR DISEASE RISK VIA ANALYSIS OF IgG GLYCOME

The present disclosure reveals a process for the determination of a risk for the development of cardiovascular disease (CVD) in the future from quantitative analysis of four specific IgG N-glycans isolated from a blood sample of examined human subjects. Said four specific glycans were found to be significant diagnostic markers by statistical analysis of the results obtained from previously performed clinical trials that revealed the variation of quantitative IgG glycans content in the blood plasma in a cohort of normal subjects, versus, those who experienced CVD clinical manifestations. From this analysis, a new numerical model was developed which enables the calculation of the CVD risk parameter (CVDR). The numerical value for CVDR obtained after the inclusion of the result of said four key glycans, obtained from the blood analysis, gives an assessment of the eventual CVD development in the examined subject in the future.
Owner:GENOS D O O +1

Biomarker for detecting kidney fibrosis related diseases and application thereof

The invention belongs to the technical field of medicines, and particularly discloses a biomarker for detecting kidney fibrosis related diseases and application of the biomarker. The biomarker comprises serum copper cyanin, or the serum copper cyanin and serum creatinine. Compared with other methods for diagnosing renal fibrosis, the serum cupreuloplasmin has the following three advantages: 1, compared with a conventional diagnostic marker (such as serum creatinine), the cupreuloplasmin can detect up-regulation in the serum of a patient suffering from early chronic kidney diseases, and can be combined with an existing mature diagnostic marker for detection; secondly, compared with renal tissue pathologic biopsy, the use of the copper cyanin as the diagnostic marker has non-invasiveness, and only a small amount or even a trace amount of patient serum is needed, so that the harm to the body health of the patient is avoided; and thirdly, compared with a nuclear magnetic resonance method for analyzing the metabolic components of the urine, the method for detecting the markers in the serum is lower in cost, more flexible, high in timeliness and easier to popularize.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Application of macrophage LSR in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy

The invention belongs to the technical field of biological medicine, and particularly relates to application of macrophage LSR gene and / or LSR protein in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Research finds that the LSR deletion of macrophages aggravates renal injury by promoting inflammatory response of diabetic nephropathy and increasing lipid renal toxicity; on the contrary, after the LSR expression of the macrophages is recovered, the inflammatory response and lipid droplet deposition of the kidney of the diabetic nephropathy mouse can be effectively reduced, and meanwhile, the kidney injury is improved. Cell experiments show that LSR deletion of macrophages can activate a YAP signal channel to increase secretion of inflammatory factors and reduce low-density lipoprotein uptake at the same time. Therefore, the macrophage LSR can be used as a diabetic nephropathy drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.
Owner:BINZHOU MEDICAL COLLEGE

Diagnostic marker for Parkinson's disease, application of diagnostic marker and heteropolymer detection method

The invention discloses a diagnostic marker for Parkinson's disease, application of the diagnostic marker and a heteropolymer detection method, and relates to the technical field of biology. The diagnostic marker is a protein heterozygous aggregate in a brain-derived exosome, and the protein heterozygous aggregate comprises alpha-synuclein and amylin. The invention also provides application of a reagent for detecting the diagnostic marker in preparation of a diagnostic product for Parkinson's disease. According to the present invention, the research results show that the important biomarker protein aggregate in the Parkinson's disease diagnosis is not the aggregate simply formed by polymerizing the alpha-Synuclein (aS) protein, but is doped with the other easily aggregated protein-amylin (Amylin); a heteropolymer composed of aS and Amylin is adopted as a biomarker, and the diagnosis efficiency on the Parkinson's disease can be effectively improved.
Owner:THE CHINESE UNIV OF HONG KONG (SHENZHEN) +1